XBiotech Inc. (XBIT) Stock Analysis & Investment Frameworks
XBiotech Inc. (XBIT) stock analysis on Invetso. Review XBiotech Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
XBiotech Inc. Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
XBiotech Inc. Key Financial Metrics
- Market Cap: $60.67M
- Revenue: $N/A
- ROE: -31.62%
- ROIC: -37.01%
- Dividend Yield: N/A
About XBiotech Inc.
XBiotech Inc. is a biopharmaceutical firm specializing in the discovery, development, and commercialization of True Human monoclonal antibodies. Their primary focus involves building a robust pipeline of product candidates aimed at combating both inflammatory and infectious diseases. Furthermore, the company is advancing interleukin-1 alpha-based therapies, which are designed to address a broad spectrum of medical conditions such as cancer, stroke, heart attack, and arthritis. Interleukin-1 alpha itself plays a crucial role in biological processes like tissue breakdown, angiogenesis, blood clot formation, malaise, muscle wasting, and inflammation. Additionally, XBiotech is developing a True Human COVID-19 therapy specifically targeting mutant strains of the virus. Established in 2005, XBiotech Inc. maintains its headquarters in Austin, Texas.
XBiotech Inc. Investment Frameworks
Invetso analyzes XBiotech Inc. (XBIT) across the following frameworks:
- XBiotech Inc. 10Y Growth Potential
- XBiotech Inc. Scenario Analysis
- XBiotech Inc. Risks & Opportunities
- XBiotech Inc. Economic Moat
- XBiotech Inc. Business Model
- XBiotech Inc. Management
- XBiotech Inc. SWOT Analysis
- XBiotech Inc. Porter's 5 Forces
- XBiotech Inc. PESTLE Analysis
- XBiotech Inc. ESG Analysis